The current notice periods for Directors are 3 months for the Chairman, 1 month for non-executive Directors and six months for Stephen Stamp. The Group has no specific policy on loss of office other ...

In mouse thymocytes, positive regulation of inducible T cell kinase (ITK) membrane recruitment by InsP 4 establishes a feedback loop of phospholipase Cγ1 activation downstream of the T cell ...

Cover picture: Drosophila adult thorax split in half with all nuclei in blue, all muscles in green and the 100s of nuclei of the large flight muscles in red. FM image provided by the authors of the ...

Cover picture: Drosophila adult thorax split in half with all nuclei in blue, all muscles in green and the 100s of nuclei of the large flight muscles in red. FM image provided by the authors of the ...

For immunoblots, anti-mouse Lyn, anti-mouse phospho-Syk (Try532), TRAF2/3/6 antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-mouse Akt, anti-mouse phospho-Akt (Ser473) ...

为探究 TLR4-Lyn 通路在阿尔茨海默病（AD）中的作用，研究人员以 WT、5XFAD 和 5XFAD x Lyn-/-小鼠为模型开展研究。结果发现 Lyn 激酶可调节 TLR4 诱导的炎症和 Syk 诱导的保护，TLIMs 能改善 AD 症状，为 AD 治疗提供新策略。 在神经科学领域，阿尔茨海默病（Alzheimer’s ...

Your body produces the enzyme creatine kinase (CK) or creatine phosphokinase to keep your muscles functioning properly. Healthcare providers use the CK test to check levels of this protein in your ...

LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed as a potential treatment option for B-cell non-Hodgkin lymphoma (B-NHL). While Bruton's Tyrosine Kinase (BTK ...

Oral and poster presentations of its DZD8586 study results in chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL) are selected by ASCO Scientific Program Committee. In ...

Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. Shares of BDRX stock traded down $0.06 ...

DZD8586 is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed as a potential treatment option for B-cell non-Hodgkin lymphoma (B-NHL).